Gensight Biologics Aktie [WKN DE: A2ANGZ / ISIN: FR0013183985]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Gensight Biologics SA

13.11.24		GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France (Businesswire)
28.10.24		GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ® (Businesswire)
24.10.24		GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update (Businesswire)
17.10.24		GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024 (Businesswire)
23.09.24		GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates (Businesswire)
23.07.24		GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update (Businesswire)
11.07.24		GenSight Biologics Launches Newsletter for Retail Investors (Businesswire)
20.06.24		GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates (Businesswire)
04.06.24		GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings (Businesswire)
03.06.24		GenSight Biologics Appoints William Monteith to its Board of Directors (Businesswire)
18.04.24		GenSight Biologics Announces the Filing of its 2023 Universal Registration Document (Businesswire)
04.04.24		GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update (Businesswire)
04.04.24		GenSight Biologics Announces its 2024 Financial Calendar (Businesswire)
22.03.24		GenSight Biologics Reports Full Year 2023 Consolidated Financial Results (Businesswire)
20.03.24		GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration (Businesswire)
12.03.24		GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024 (Businesswire)
06.03.24		GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024 (Businesswire)
15.03.23		GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023 (Businesswire)
13.03.23		GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial (Businesswire)
09.03.23		GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology (Businesswire)
13.02.23		GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa (Businesswire)
15.12.22		GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy (Businesswire)
20.07.22		GenSight Biologics: 5 Years' Data Shows Sustained Efficacy Of LUMEVOQ (RTTNews)
20.07.22		GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ® (Businesswire)
19.05.22		GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology (Businesswire)
24.01.22		GenSight Announces Vision Improvement Maintained 4 Yrs After Treatment With LUMEVOQ Gene Therapy (RTTNews)
24.01.22		GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy (Businesswire)
14.12.21		GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial (Businesswire)
12.10.21		GenSight Gets Fast Track Designation For Optogenetic Therapy GS030 To Treat Retinitis Pigmentosa (RTTNews)
05.07.21		GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France (Businesswire)
30.06.21		GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment (Businesswire)
10.06.21		GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering (Businesswire)
01.06.21		GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology (Businesswire)
31.05.21		GenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment (Businesswire)
19.05.21		GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch (Businesswire)
17.05.21		GenSight Biologics Appoints Françoise de Craecker to its Board of Directors (Businesswire)
03.05.21		GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye (Businesswire)
20.04.21		GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update (Businesswire)
10.03.21		GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021 (Businesswire)
15.02.21		GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs (Businesswire)
04.02.21		GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non-Human Primates (Businesswire)
19.01.21		GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update (Businesswire)
18.01.21		GenSight Biologics Announces its 2021 Financial Calendar (Businesswire)
13.01.21		GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology® (Businesswire)
10.12.20		GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital (Businesswire)
10.12.20		GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine (Businesswire)
03.11.20		GenSight Biologics Reports Validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency (Businesswire)
21.10.20		GenSight Biologics Launches a Capital Increase of Approximately €25 Million by Means of an Accelerated Bookbuilding Process (Businesswire)
15.09.20		GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
06.07.20		GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer Mobility-Aktie schwach: Gehälter für Angestellte von insolventer KTM noch vor Weihnachten

UNIQA Insurance-Aktie im Plus: UNIQA plant zu expandieren und Dividenden zu erhöhen

Ethereum Kurs Prognose: ETH massiv unterbewertet! Fällt jetzt das ATH?

Bundesheer wirbt nach KTM-Insolvenz um Mitarbeiter - Pierer Mobility-Aktie im Plus

EZB wird wohl Leitzinsen senken - wie stark?

OMV-Aktie verliert: OMV kündigt Liefervertrag mit Gazprom

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	14.12.2024 08:15
Kaufwert:	EUR
	Hinzufügen Speichern